Manav Mehta
Principal investigator.
Medtech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2016First federal award
$14.2MFederal grants as PI20 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
20 awards · $14.2M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jun 25, 2026 | NIH | SBIR Phase II Novel dermal templates for prevention and treatment of biofilms in cutaneous wounds | $1.0M | GEL4MED, INC. |
| Jun 17, 2025 | NIH | SBIR Phase II Novel dermal templates for prevention and treatment of biofilms in cutaneous wounds | $1.1M | GEL4MED, INC. |
| Aug 29, 2024 | NIH | SBIR Phase II Antimicrobial dermal matrices to promote infection free wound closure in DTU-DFUs. | $1.5M | GEL4MED, INC. |
| Sep 15, 2023 | NIH | SBIR Phase II Antimicrobial dermal matrices to promote infection free wound closure in cutaneous wounds | $1.2M | GEL4MED, INC. |
| Aug 31, 2023 | NIH | SBIR Phase II Antimicrobial dermal matrices to promote infection free wound closure in DTU-DFUs. | $1.1M | GEL4MED, INC. |
| Jan 27, 2022 | NIH | SBIR Phase II TABA funding for the Fast Track project "ANTIMICROBIAL DERMAL MATRICES TO PROMOTE INFECTION FREE WOUND CLOSURE IN CUTANEOUS WOUNDS_R44GM133305" | $50K | GEL4MED, INC. |
| Mar 22, 2021 | NIH | SBIR Phase II Antimicrobial dermal matrices to promote infection free wound closure in cutaneous wounds | $980K | GEL4MED, INC. |
| Jan 25, 2021 | NIH | SBIR Phase I Treatment of microbial keratitis and corneal wound healing | $30K | GEL4MED, INC. |
| Aug 14, 2020 | NIH | SBIR Phase I Antifungal Dermal Templates for Wound Healing | $300K | GEL4MED, INC. |
| Jun 30, 2020 | NIH | SBIR Phase I Treatment of microbial keratitis and corneal wound healing | $380K | GEL4MED, INC. |
| Apr 1, 2020 | NIH | SBIR Phase II TABA funding for the Fast Track project "ANTIMICROBIAL DERMAL MATRICES TO PROMOTE INFECTION FREE WOUND CLOSURE IN CUTANEOUS WOUNDS_R44GM133305" | $2.7M | GEL4MED, INC. |
| Mar 26, 2020 | NIH | SBIR Phase II Antimicrobial dermal matrices to promote infection free wound closure in cutaneous wounds | $1.7M | GEL4MED, INC. |
| Mar 28, 2019 | NIH | SBIR Phase II Antimicrobial dermal matrices to promote infection free wound closure in cutaneous wounds | $349K | GEL4MED, INC. |
| Mar 26, 2019 | NIH | SBIR Phase I Novel dermal templates for prevention and treatment of biofilms in cutaneous wounds | $300K | GEL4MED, INC. |
| Feb 1, 2019 | NSF | SBIR Phase I SBIR Phase I: Tunable Mechanical and Functional Properties of Peptide Films | $225K | GEL4MED, INC. |
| Jan 29, 2019 | NSF | SBIR Phase I SBIR Phase I: Tunable Mechanical and Functional Properties of Peptide Films | $225K | GEL4MED, INC. |
| Sep 22, 2017 | NIH | SBIR Phase I Management of bioburden and tissue regeneration in diabetic wounds using engineered matrices | $292K | GEL4MED, INC. |
| Sep 1, 2017 | NIH | SBIR Phase I Therapeutic cells encapsulation and delivery for improved healing of chronic diabetic wounds | $299K | GEL4MED, INC. |
| Apr 1, 2017 | NIH | SBIR Phase I Surgical Wound Closure Matrices for the Prevention of Superficial Incisional SSI | $224K | GEL4MED, INC. |
| May 6, 2016 | NIH | SBIR Phase I Flowable antimicrobial skin scaffolding matrix that promotes regeneration | $223K | GEL4MED, INC. |
1 patents as inventor
- US GEL4MED, INC.—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#26
Awards as PI#27
Patents#505
Companies
- GEL4MED, INC.Linked by awards · Medtech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.